Gabapentin市場規模、佔有率和成長分析：按類型、劑型、分銷管道、應用和地區分類－2026-2033年產業預測

2024 年全球Gabapentin市場價值 23 億美元，預計到 2025 年將成長至 24.1 億美元，到 2033 年將成長至 35.4 億美元，在預測期（2026-2033 年）內複合年成長率為 4.92%。

全球Gabapentin市場主要受專利到期後學名藥興起的推動，其特點是臨床上廣泛使用處方箋抗驚厥藥物和治療神經性疼痛。與新型替代藥物相比，加巴噴丁的成本績效效益確保了其穩定的需求，而監管和處方模式的轉變則顯著影響市場動態。學名藥的興起降低了價格，提高了患者的用藥可及性，迫使生產商最佳化其供應鏈。人工智慧的進步正在革新需求預測，使預測模型能夠考慮處方趨勢、運輸模式和醫療支付方的行為，從而增強庫存管理。由於醫療預算緊張，保險公司對仿單標示外用藥施加限制，生產商在適應臨床醫生對低成本疼痛管理方案偏好變化的同時，也受益於合規的供應鏈。

全球Gabapentin市場的成長要素

全球Gabapentin市場成長的驅動力在於對有效治療方法神經病變疼痛和癲癇的需求不斷成長。隨著越來越多的患者被診斷出患有慢性神經病變疾病，對長期管理方案的需求日益增加，而Gabapentin因其確切療效，正被醫療專業人員更頻繁地處方使用。隨著其治療效果日益被臨床醫生認可，轉診和持續處方的模式正在形成，這促使製藥公司加強其生產和分銷能力。這些醫療保健領域的綜效正在擴大市場需求，從而提高治療方案的一致性，並進一步擴大市場在各種醫療保健機構中的滲透率。

全球Gabapentin市場的限制因素

由於監管要求日益嚴格以及安全警告的變更，全球Gabapentin市場面臨許多限制。這些因素可能限制該藥物的核准用途，並影響醫師對仿單標示外用藥的信心。當監管機構實施更嚴格的風險溝通標準或強制要求額外的上市後監測時，製造商往往面臨更長的研發週期和更重的合規責任。這種情況可能阻礙促銷活動，並抑制市場成長機會。此外，日益嚴格的審查可能導致醫療專業人員選擇替代療法或採取更謹慎的處方態度，最終減緩Gabapentin處方量的成長，並影響市場動態。

全球Gabapentin市場趨勢

全球Gabapentin市場正經歷一個顯著的趨勢，即其治療適應症正超越傳統用途而不斷擴展。隨著仿單標示外在神經病變疼痛和其他疼痛相關疾病方面的非適應症用途被探索，臨床醫生的認知度不斷提高，患者的需求也不斷成長。為了因應這一成長趨勢，製藥公司正在積極探索擴大策略，並與學術機構合作，以檢驗在不同患者群體中的臨床療效。隨著Gabapentin作為治療方法的接受度不斷提高，其在健保覆蓋範圍內的地位也日益穩固，促使保險公司重新審視其福利政策。因此，這一趨勢為建立差異化的臨床證據、制定策略性的市場進入策略以及加強對醫療專業人員的教育培訓計畫創造了契機。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球Gabapentin市場規模：按類型分類

• 非專利的
• 品牌
• 其他

全球Gabapentin市場規模（以劑型分類）

• 藥片
  • 速釋製劑
  • 緩釋
• 膠囊
• 口服液
• 其他

全球Gabapentin市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房
• 其他

全球Gabapentin市場規模：按應用領域分類

• 癲癇
• 神經病變疼痛
  • 糖尿病神經病變
  • 帶狀皰疹後遺症神經痛
• 不寧腿
• 其他

全球Gabapentin市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Pfizer
• Teva Pharmaceutical Industries
• Mylan
• Apotex
• Sun Pharmaceutical Industries
• Aurobindo Pharma
• Cipla
• Lupin
• Zydus Lifesciences
• Glenmark Pharmaceuticals
• Torrent Pharmaceuticals
• Ipca Ltd
• Rochem International
• Accord Healthcare
• Strides Pharma Science
• Ascend Laboratories
• Hetero Drugs
• Sandoz
• Wockhardt
• Amneal Pharmaceuticals

結論與建議

Global Gabapentin Market size was valued at USD 2.3 Billion in 2024 and is poised to grow from USD 2.41 Billion in 2025 to USD 3.54 Billion by 2033, growing at a CAGR of 4.92% during the forecast period (2026-2033).

The global gabapentin market, primarily driven by generics resulting from patent expirations, is characterized by its wide clinical adoption for prescription anticonvulsant use and neuropathic pain management. Its cost-effectiveness compared to newer alternatives ensures consistent demand, while regulatory scrutiny and shifting prescribing patterns significantly influence market dynamics. The rise of generics has led to price compression and improved patient access, compelling manufacturers to optimize supply chains. Advancements in AI are revolutionizing demand forecasting, enabling predictive models that consider prescription trends, shipment patterns, and payer dynamics, thus enhancing inventory management. As healthcare budgets tighten and insurers impose restrictions on off-label uses, manufacturers benefit from compliant supply chains while adapting to evolving clinician preferences for lower-cost options in pain management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gabapentin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gabapentin Market Segments Analysis

Global gabapentin market is segmented by type, dosage form, distribution channel, application and region. Based on type, the market is segmented into Generic, Branded and Others. Based on dosage form, the market is segmented into Tablet, Capsule, Oral Solution and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on application, the market is segmented into Epilepsy, Neuropathic Pain, Restless Legs Syndrome and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gabapentin Market

The Global Gabapentin market is significantly influenced by the growing demand for effective treatments for neuropathic pain and seizures. As more individuals are diagnosed with chronic neuropathic conditions, the need for long-term management solutions increases, leading healthcare providers to increasingly prescribe gabapentin due to its established effectiveness. The rising recognition of its therapeutic benefits among clinicians fosters a culture of referrals and continuous prescriptions, which spurs pharmaceutical companies to enhance their production and distribution capacities. This synergy among healthcare practices amplifies market demand, resulting in more consistent treatment regimens and broader market penetration across various medical settings.

Restraints in the Global Gabapentin Market

The global gabapentin market faces significant constraints due to stringent regulatory requirements and changing safety warnings, which can limit the drug's approved uses and affect physicians' confidence in prescribing it for off-label purposes. When regulatory agencies impose stricter risk communication standards or mandate further post-marketing research, manufacturers are often burdened with longer timelines and heightened compliance responsibilities. This situation can hinder promotional activities and stifle market growth opportunities. Additionally, increased scrutiny may prompt healthcare providers to opt for alternative treatments or adhere to more cautious prescribing habits, ultimately slowing down the increase in gabapentin prescriptions and impacting overall market dynamics.

Market Trends of the Global Gabapentin Market

The global gabapentin market is experiencing a notable trend characterized by the expansion of therapeutic indications beyond its traditional use. Increased exploration of off-label applications for neuropathic pain and other pain-related conditions is enhancing clinician familiarity and driving patient demand. This surge in interest is prompting manufacturers to engage in label expansion strategies and collaborate with academic institutions for clinical validation across diverse patient populations. As therapeutic acceptance grows, gabapentin's positioning within formularies strengthens, encouraging payers to reevaluate coverage policies. Consequently, this dynamic creates avenues for differentiated clinical evidence, strategic market access initiatives, and enhanced education programs for healthcare providers.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Gabapentin Market Size by Type & CAGR (2026-2033)

• Market Overview
• Generic
• Branded
• Others

Global Gabapentin Market Size by Dosage Form & CAGR (2026-2033)

• Market Overview
• Tablet
  • Immediate-Release
  • Extended-Release
• Capsule
• Oral Solution
• Others

Global Gabapentin Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Gabapentin Market Size by Application & CAGR (2026-2033)

• Market Overview
• Epilepsy
• Neuropathic Pain
  • Diabetic Neuropathy
  • Postherpetic Neuralgia
• Restless Legs Syndrome
• Others

Global Gabapentin Market Size & CAGR (2026-2033)

• North America (Type, Dosage Form, Distribution Channel, Application)
  • US
  • Canada
• Europe (Type, Dosage Form, Distribution Channel, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Dosage Form, Distribution Channel, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Dosage Form, Distribution Channel, Application)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Dosage Form, Distribution Channel, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apotex
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipca Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rochem International
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Accord Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Strides Pharma Science
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ascend Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hetero Drugs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wockhardt
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations